These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1362374)

  • 41. The prognostic value of TSH receptor binding and thyroid stimulating antibodies following antithyroid drug treatment of Graves' disease.
    Wilson R; Fraser WD; McKillop JH; Thomson JA
    Acta Endocrinol (Copenh); 1989 Nov; 121(5):666-70. PubMed ID: 2573989
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Studies of autoimmunity in Graves' disease before and after treatment with carbimazole.
    Zosin I; Arcan P; Lungu G; Cotoi A; Opreanu R
    Endocrinologie; 1988; 26(1):49-53. PubMed ID: 3260398
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thyrotropin receptor antibodies in hypothyroid Graves' disease.
    Kasagi K; Hidaka A; Nakamura H; Takeuchi R; Misaki T; Iida Y; Konishi J
    J Clin Endocrinol Metab; 1993 Feb; 76(2):504-8. PubMed ID: 8094394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Triiodothyronine generation from thyroxine in human thyroid: enhanced conversion in Graves' thyroid tissue.
    Ishii H; Inada M; Tanaka K; Mashio Y; Naito K; Nishikawa M; Imura H
    J Clin Endocrinol Metab; 1981 Jun; 52(6):1211-7. PubMed ID: 6894450
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical analysis in intact erythrocytes using 1H spin echo NMR.
    Reglinski J; Smith WE; Wilson R; Buchanan LM; McKillop JH; Thomson JA; Brzeski M; Marabani M; Sturrock RD
    Clin Chim Acta; 1991 Sep; 201(1-2):45-57. PubMed ID: 1790625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum cytokines in thyrotoxicosis.
    Siddiqi A; Monson JP; Wood DF; Besser GM; Burrin JM
    J Clin Endocrinol Metab; 1999 Feb; 84(2):435-9. PubMed ID: 10022397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assays for thyrotropin-receptor binding and thyroid-stimulating antibodies in sera from patients with Graves' disease.
    Massart C; Hody B; Mouchel L; Edan G; Nicol M
    Clin Chem; 1986 Jul; 32(7):1332-5. PubMed ID: 2872980
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
    Kawai K; Tamai H; Matsubayashi S; Mukuta T; Morita T; Kubo C; Kuma K
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):551-6. PubMed ID: 8548939
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Congenital thyrotoxicosis in premature infants.
    Smith C; Thomsett M; Choong C; Rodda C; McIntyre HD; Cotterill AM
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):371-6. PubMed ID: 11298090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
    Baldini M; Castagnone D; Rivolta R; Meroni L; Pappalettera M; Cantalamessa L
    Thyroid; 1997 Dec; 7(6):823-8. PubMed ID: 9459623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease.
    Harper L; Chin L; Daykin J; Allahabadia A; Heward J; Gough SC; Savage CO; Franklyn JA
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):671-5. PubMed ID: 15163328
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relapse of Graves' disease after medical therapy: predictive value of thyroidal technetium-99m uptake and serum thyroid stimulating hormone receptor antibody levels.
    Wilson R; McKillop JH; Pearson DW; Cuthbert GF; Thomson JA
    J Nucl Med; 1985 Sep; 26(9):1024-8. PubMed ID: 2863338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Insulin autoantibodies before and after carbimazole therapy in Asian Indian patients with Graves' disease.
    Goswami R; Jayasuryan N; Jaleel A; Tandon N; Kochupillai N
    Diabetes Res Clin Pract; 1998 Jun; 40(3):201-6. PubMed ID: 9716924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The 20-minute iodine uptake in Graves' disease. 2. Natural course during medical treatment (author's transl)].
    Wilkin TJ; Crooks J; Jaffiol C; Baldet L
    Ann Endocrinol (Paris); 1981; 42(2):113-20. PubMed ID: 6895290
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of long-term antithyroid drug treatment on serum reverse T3 in patients with Graves' disease.
    Dahlberg PA; Karlsson FA; Wide L
    Acta Med Scand; 1980; 207(5):375-8. PubMed ID: 6155758
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thyrotrophin binding inhibiting immunoglobulins in Graves' disease before, during and after antithyroid therapy, and its relation to long-acting thyroid stimulator.
    Docter R; Bos G; Visser TJ; Hennemann G
    Clin Endocrinol (Oxf); 1980 Feb; 12(2):143-53. PubMed ID: 6105023
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical analysis by 1H spin-echo NMR. 2. Oxidation of intracellular glutathione as a consequence of penicillamine therapy in rheumatoid arthritis.
    Reglinski J; Smith WE; Brzeski M; Marabani M; Sturrock RD
    J Med Chem; 1992 May; 35(11):2134-7. PubMed ID: 1597863
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
    Aizawa T; Ishihara M; Koizumi Y; Hashizume K; Takasu N; Yamada T; Kobayashi I; Watanabe T; Shimizu Z
    Am J Med; 1990 Aug; 89(2):175-80. PubMed ID: 2166430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.